New treatment for reducing excess iron in the body
Official title: Long-Acting, Short-Residing Nanochelators for Iron Overload Therapy
Funded at Massachusetts General Hospital · NIH-11002667 · Data updated 2026-11-12
This study is testing a new treatment that uses tiny particles to help people with thalassemia and sickle cell anemia get rid of extra iron in their bodies, making it easier and safer for them to manage their condition without needing lots of shots or pills.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $645,497 |
| NIH project number | 5R01HL163273-03 |
| Project ID | NIH-11002667 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with conditions that lead to iron overload, such as thalassemia, sickle cell anemia, or other chronic anemias requiring frequent blood transfusions.
✕Less likely to help
Patients who do not have iron overload or related conditions may not benefit from this research.
What this research studies
This research focuses on developing long-acting nanochelators that can effectively reduce excess iron in patients, which is crucial for those suffering from conditions like thalassemia and sickle cell anemia. The approach aims to improve patient compliance by minimizing the need for frequent injections or oral medications that can have significant side effects. By utilizing advanced nanotechnology, the study seeks to create a more effective and safer method for managing iron overload, which is linked to serious health issues such as heart and liver failure. Patients will be monitored for their response to this innovative treatment over the course of the study.
Why it matters
Potential benefit: If successful, this research could provide a more effective and patient-friendly treatment option for managing iron overload, potentially reducing complications associated with chronic anemia.
How similar studies have gone: Previous research has shown promise in using chelators for iron overload therapy, but this approach with long-acting nanochelators is relatively novel and untested.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Choi, Hak Soo — Massachusetts General Hospital
- Study coordinator: Choi, Hak Soo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.